Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Teva Pharmaceutical (TEVA)

38.33

+1.24 (3.34%)

as of Sep 14, 2026, 7:59:59 pm Market Open.

70 watching

Investor Insights

Sep 14, 2026, 12:00 am

This summary was created by AI, based on 5 opinions in the last 12 months.

Teva Pharmaceutical is experiencing a turnaround under its current CEO, with a significant 264% increase since January 2023. The company's growth strategy is yielding positive results, which has recently led to an upgrade in its credit rating by Moody's to investment grade. Factors contributing to this positive outlook include a diverse revenue stream, improving operating margins, strong free cash flow, and an expanding pipeline of innovative products. Despite facing challenges in the generic drug market and criticism about its innovation, expert opinions suggest that Teva remains a strong candidate within the healthcare sector, bolstered by solid cash reserves and expectations for further debt reduction. Analysts project a positive price trajectory for the stock, indicating growth potential over the coming months.

Consensus

Positive

Valuation

Undervalued

Similar

Novartis, NVS

DON'T BUY

Global leader with about 60% of revenues from US. Generics have recently under performed because of regulatory changes that are squeezing profitability. Generics will continue to expand market share. Acquisitions can take time for results to show in the numbers. Trading below 200 day moving average. Would prefer to see if trading above $60.

HOLD

Owns half as much as he used to. Worried about their biggest non-generic product. It’s an MS drug with a lot of controversy.

COMMENT

Generic drugs are going to thrive. Cost of drugs is killing global governments that pay for them. The solution is generics that typically cost a fraction. He is wary of the entire pharmaceutical industry.

TOP PICK

Likes the generic space. Expects there will be increasing appetite for governments globally to spend less on health care. Have some very aggressive growth targets for the next 4-5 years. Have been very good at doing acquisitions.

PAST TOP PICK

(A Top Pick May 6/09. Up 37% excluding dividends.) Largest global generic manufacturer. Made acquisitions that strengthens them geographically. Trend towards generics is going to continue.

TOP PICK

Largest manufacturer of generic drugs. Have a pipeline potential of over $100 billion over the next 5 years as patents come off from large pharmaceuticals. Seriously undervalued.

DON'T BUY

Half business is generic drugs. US health care companies are reporting. New US reform will cause increased rebates to Medicaid. This is primary reason for TEVA coming off along with the group.

COMMENT

Generics continue to get wins in terms of shortened time frames as to pharmaceuticals staying on patents.

PAST TOP PICK

(A Top Pick Jan 28/09. Up 34.77%.) Buy on weakness.

TOP PICK

Dominant generics player globally. Has 25% of the generic market in the US. Expecting some form of health care will pass in the US, which will bring 20-40 million people into the health-care system. Trading at only about 15X earnings. Very strong growth prospects.

PAST TOP PICK

(A Top Pick Nov 11/08. Up 24.69%.) Still likes.

BUY

More and more major drugs are coming off patent over the next few years. Being the biggest they will get the lion’s share.

TOP PICK

(A Top Pick May 11/09. Up 12.75%.) Has been in a great uptrend for many years. Thinks you will be able to buy this on a pullback within the next 30 days or so. Fundamentals are good on this company.

PAST TOP PICK

(A Top Pick Oct 14/08. Up 23.38%.) World's largest generic drug company. Also have some branded drugs that are doing very well.

COMMENT

Hasn't added this to portfolios because he is a little bit wary about the generic drug construct in the market and the possibility of the patent drug makers to move into that space. He wouldn't hesitate to have anybody look closely at this one however. Might be slightly overpriced. (See Top Picks.)

Showing 181 to 195 of 277 entries

Most Recent Experts

Ryan Bushell

Newhaven Asset Management

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Cerity Partners

Joe Terranova

Virtus Investment Partners

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Teva Pharmaceutical (TEVA)